Core Viewpoint - Kanghua Biotech (300841.SZ) has officially launched Phase I clinical trials for its recombinant hexavalent norovirus vaccine (Pichia pastoris) in mainland China, marking a significant step in the development of a vaccine aimed at preventing norovirus infections and the acute gastroenteritis they cause [1] Group 1: Vaccine Development - The recombinant hexavalent norovirus vaccine (Pichia pastoris) is designed to prevent norovirus infections and the resulting acute gastroenteritis [1] - Norovirus is a major pathogen responsible for acute gastroenteritis outbreaks across all age groups globally, with no approved treatment or preventive vaccine currently available [1] - The vaccine utilizes innovative genetic engineering technology based on virus-like particles (VLPs), theoretically capable of preventing over 90% of norovirus infections and related acute gastroenteritis [1]

Core Viewpoint - The approval of Rongpei growth hormone injection by the National Medical Products Administration (NMPA) marks a significant advancement in the treatment of pediatric growth hormone deficiency (PGHD) in China, offering a long-acting alternative that has demonstrated superior efficacy compared to daily injections [1][2]. Company Summary - Weisheng Pharmaceutical's Rongpei growth hormone is the first and only long-acting growth hormone in China that has passed phase III clinical trials, showing a higher annualized growth rate compared to daily formulations [1]. - The product is expected to enhance the company's brand presence in the Greater China region, leveraging its clinical validation in the U.S. and successful phase III trial results in the Chinese population [2]. - The company plans to adopt a dual approach for market entry, focusing on both original imports and future local production partnerships [9]. Industry Summary - The Chinese growth hormone market has seen rapid growth, expanding from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, projected to reach 28.6 billion yuan by 2030 [4]. - The market is transitioning from volume expansion to value competition, with long-acting growth hormones expected to dominate the market by 2030, capturing 80% of the market share [4][5]. - The competitive landscape is characterized by a shift towards long-acting formulations, with existing players facing challenges from price competition and the need for differentiation [5][10]. Market Dynamics - The approval of Rongpei growth hormone is anticipated to provide a more convenient treatment option for pediatric patients, potentially increasing market penetration in a segment that has historically lagged behind developed countries [2]. - The market is experiencing a structural change, with a growing emphasis on long-acting products, which are expected to become a significant segment of the market [5][9]. - The pricing landscape is evolving, with recent price adjustments for long-acting growth hormones aimed at improving accessibility and creating a divide between "insurance-inclusive" and "high-end quality" segments [8][9]. Technological Advantages - Rongpei growth hormone utilizes TransCon technology, which allows for a slow release of growth hormone that mimics the natural structure of human growth hormone, providing a theoretical safety advantage over other long-acting products [6][7]. - The product's mechanism of action involves both indirect (80% via IGF-1) and direct pathways (20% directly on growth plates), enhancing its efficacy in promoting height growth [7]. Challenges Ahead - Despite its technological advantages, the commercialization of Rongpei growth hormone faces challenges, particularly regarding pricing and reimbursement issues, as many families are concerned about out-of-pocket costs [8][10]. - The company must navigate hospital access barriers and the evolving reimbursement landscape, which could impact the product's market penetration [8][9].

Core Viewpoint - Anke Bio (300009) is actively advancing the overseas licensing of innovative drugs through its subsidiary, Boshengji, and will disclose results appropriately when available [1] Group 1: Company Developments - The company is focusing on companies that utilize AI platform technology as a core technology [1] - The review of Longpei growth hormone is nearing completion with the National CDE [1]

公募基金持股方面，工银瑞信前沿医疗股票型证券投资基金持股数量为380万股，占公司流通股比例 0.62%，位列第八大流通股东；中欧医疗健康混合型证券投资基金持股数量达335.06万股，占流通股比 例0.54%，为第十大流通股东。 数据显示，截至2025年9月30日，公司前十大流通股东合计持有5.36亿股，占公司流通股比例达 86.83%。富健药业有限公司以2.22亿股的持股数量位居首位，占流通股比例35.92%；上海兴生药业有限 公司持股2.13亿股，占比34.48%，为第二大流通股东；沈阳三生制药有限责任公司、达佳国际（香港） 有限公司分别持股3961.46万股、2516.07万股，位列第三、四位。 此外，上海浦东田羽投资发展中心（有限合伙）、Grand Path Holdings Limited、上海浦东领驭投资发展 中心（有限合伙）、上海翃熵投资咨询有限公司等机构股东在三季度保持持股稳定，未进行增减持操 作，持股数量分别为1096.54万股、1040.89万股、437.57万股、371.75万股，占流通股比例依次为 1.78%、1.69%、0.71%、0.60%。 中证报中证网讯（记者 傅苏颖）1月26日 ...

中证报中证网讯(记者张鹏飞)近日，浙江省经济和信息化厅公布2025年度省级"专精特新"中小企业名 单，步长制药（603858）旗下浙江天元生物药业有限公司凭借在生物制药领域的"专精特新"发展优势成 功入选，标志着其核心竞争力获得权威认可。 作为步长制药在生物药、疫苗领域的战略核心载体，浙江天元生物药业深耕生物制药细分赛道，持续构 建差异化竞争优势，此次入选是其坚守"专精特新"发展路径、深耕细作的必然成果。 精细化管理上，公司严格遵循医药行业高标准规范，建立覆盖研发、生产、仓储、流通全流程的质量管 控体系，近三年无重大安全质量事故，以规范稳健的经营表现顺利通过各项审核。 此次获评省级"专精特新"企业，印证了步长制药多元产业生态布局的战略优势。未来，天元生物将借力 政策红利，进一步加大研发投入力度，聚焦生物药与疫苗领域的技术创新与产品迭代，持续提升核心竞 争力，为区域健康产业高质量发展注入新动能。 专业化布局上，公司聚焦疫苗与生物制品的研发、生产与转化，核心产品精准对接重大疾病防治临床需 求，多款重点项目已顺利进入临床试验阶段。 创新能力建设上，依托步长制药研发投入支撑，天元生物构建了完善的自主创新体系，研发费用 ...

Core Viewpoint - Tonghua Dongbao (600867) is expected to achieve a net profit of approximately 1.242 billion yuan in 2025, marking a turnaround from losses in the previous year [2] Group 1: Financial Performance - The company anticipates a significant increase in net profit due to its competitive advantage in the insulin procurement process, leading to rapid growth in products like Aspart and Glargine [2] - The domestic sales revenue is expected to rise sharply, driven by strong performance from multiple product categories, including Liraglutide injection and Empagliflozin tablets [2] Group 2: International Strategy - The company's internationalization strategy has shown significant results, with noticeable growth in export revenue [2] Group 3: Asset Management - The transfer of equity in Xiamen Tebao Biological Engineering Co., Ltd. has generated additional income, contributing to the substantial increase in net profit [2]

（文章来源：证券日报） 证券日报网讯 1月26日，通化东宝发布公告称，公司预计2025年年度实现归属于母公司所有者的净利润 约为124213万元，与上年同期相比，将实现扭亏为盈。 ...

智通财经APP讯，特宝生物(688278.SH)发布公告，公司拟向不特定对象发行可转债，募集资金总额(含 发行费用)不超过15.33亿元(含本数)，扣除发行费用后的募集资金净额将用于：新药研发项目、生物技 术创新融合中心建设项目、特宝生物创新药物生产改扩项目-产线建设。 ...

会上，2025年奉贤区"揭榜挂帅"合作项目签约，莱士血液、自然堂、如昂超声波等区内重点企业与复旦 大学、上海交通大学等高校达成多项合作。中国科学院上海高等研究院、上海交通大学、毅达资本等10 家机构成为"南上海科创中心生态合作伙伴"，一批来自高校、产业与投资领域的专家成为"南上海科创 人才创业导师"，为区域创新提供智力与资源支撑。 上海市研发公共服务平台管理中心、创业邦与奉贤区科委、上海市城市设计与城市科学重点实验室分别 与东方美谷集团签订合作协议，共同构建资源共享、服务联动的创新支撑体系。 现场还发布了奉贤区科技政策包，政策涵盖企业培育、成果转化、人才引育等多方面内容，为科技企业 发展、科技创新突破提供政策保障。 （文章来源：新华财经） 新华财经上海1月26日电（记者李荣）上海奉贤大力推动科技创新与产业创新的深度融合，聚力打造"热 带雨林式"创新生态体系，以高水平科技创新引领新质生产力发展。记者26日从2026南上海科创大会上 获悉，奉贤正与各方携手共建南上海科创中心。 上海市科学技术委员会相关人士介绍，上海正全力推进国际科技创新中心建设从"建框架"向"强功能"跨 越，奉贤作为上海南部重要战略空间和增长极， ...

Core Viewpoint - Tonghua Dongbao (600867) is expected to achieve a net profit of approximately 1.242 billion yuan and a net profit of approximately 402 million yuan after deducting non-recurring gains and losses in 2025, marking a significant turnaround from previous losses and a substantial recovery in performance [1] Group 1: Financial Performance - In 2025, the company anticipates a significant recovery in its financial performance, with both net profit and adjusted net profit turning positive compared to the previous year [1] - The company’s insulin similar products are projected to drive major growth, with annual sales expected to increase by over 100% year-on-year, contributing to a balanced development of its product structure [1][2] Group 2: Market Position and Strategy - Tonghua Dongbao has achieved significant improvements in market share, ranking second in the industry for human insulin and insulin similar products, with a market share of 45.5% for human insulin, maintaining the leading position domestically [2] - The company is focusing on enhancing its domestic insulin business, optimizing product structure, and expanding market share while accelerating its internationalization strategy [1][2] Group 3: Product Development and Innovation - The company has made substantial progress in international product registration, with various insulin formulations and GLP-1 products receiving approvals in multiple countries, including the U.S., Dominican Republic, and Indonesia [3] - Several R&D projects have achieved important clinical milestones, including the completion of Phase III trials for semaglutide and positive results for other diabetes-related products [4] Group 4: Shareholder Engagement - The controlling shareholder, Dongbao Industrial Group, has increased its stake in the company by investing 228 million yuan to acquire 1.42% of the shares, reflecting confidence in the company's future prospects [5] - The company plans to repurchase shares worth between 20 million and 40 million yuan to support employee stock ownership plans and/or equity incentives [5]